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Background: Since the introduction of rhBMP-2 (Infuse®) in 2002, surgeons have had an alternative substitute to
autograft and its related donor site morbidity. Recently, the prevalence of reported adverse events and complications
related to the use of rhBMP-2 has raised many ethical and legal concerns for surgeons. Additionally, the cost and
decreasing reimbursement landscape of rhBMP-2 use have required identification of a viable alternative. Osteo
allogeneic morphogenetic protein (OsteoAMP®) is a commercially available allograft-derived growth factor rich in
osteoinductive, angiogenic, and mitogenic proteins. This study compares the radiographic fusion outcomes between
rhBMP-2 and OsteoAMP allogeneic morphogenetic protein in lumbar interbody fusion spine procedures.
Methods: Three hundred twenty-one (321) patients from three centers underwent a transforaminal lumbar
interbody fusion (TLIF) or lateral lumbar interbody fusion (LLIF) procedure and were assessed by an independent
radiologist for fusion and radiographically evident complications. The independent radiologist was blinded to
the intervention, product, and surgeon information. Two hundred and twenty-six (226) patients received
OsteoAMP with autologous local bone, while ninety-five (95) patients received Infuse with autologous local
bone. Patients underwent radiographs (x-ray and/or CT) at standard postoperative follow-up intervals of
approximately 1, 3, 6, 12, and 18 months. Fusion was defined as radiographic evidence of bridging across
endplates, or bridging from endplates to interspace disc plugs. Osteobiologic surgical supply costs were also
analyzed to ascertain cost differences between OsteoAMP and rhBMP-2.
Results: OsteoAMP produced higher rates of fusion at 6, 12, and 18 months (p ≤ 0.01). The time required for
OsteoAMP to achieve fusion was approximately 40% less than rhBMP-2 with approximately 70% fewer
complications. Osteobiologic supply costs were 80.5% lower for OsteoAMP patients (73.7% lower per level) than
for rhBMP-2.
Conclusions: Results of this study indicate that OsteoAMP is a viable alternative to rhBMP-2 both clinically and
economically when used in TLIF and LLIF spine procedures.
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Table 1 Pathology breakdown















Patients presented with multiple pathologies; thus, the percentage will not
equal 100.
Table 2 Patient baseline characteristics
Characteristic OsteoAMP rhBMP-2
(n = 226) (n = 95)
Age, mean ± SD 60.0 ± 13.0 54.3 ± 10.9
Female, n (%) 131 (58.0) 56 (58.9)
Average levels/case 1.62 1.63
Operative levels, n (%)
One 147 (65.0) 72 (75.8)
Two 58 (25.7) 14 (14.7)
Three 9 (4.0) 1 (1.1)
Four 4 (1.8) 2 (2.1)
Five 3 (1.3) 1 (1.1)
Six 0 (0.0) 0 (0.0)
Seven 3 (1.3) 3 (3.2)
Eight 1 (0.4) 1 (1.1)
Twelve 1 (0.4) 1 (1.1)
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Autograft, harvested from the iliac crest, has long been
considered the ‘gold standard’ for spinal fusion. Though
the use of autograft is well studied, limited tissue availabil-
ity, donor site morbidity, and increased surgical time are
also well understood [1]. In 1965, Dr. Marshal Urist dis-
covered trace amounts of bone morphogenetic proteins
(BMPs) naturally found within the bone matrix. Since this
discovery, a wide range of allogeneic bone grafts has be-
come available as a substitute or extender to autograft [2],
yet with limited success. The goal of these allogeneic bone
grafts was to offer the greatest amount of BMP available
within the tissue, but these bone graft products are con-
strained by the small amount of BMPs found within the
actual collagen matrix [3].
In 2002, the FDA approved the use of a recombinant
human bone morphogenetic protein-2 (Infuse, Medtronic
Inc., Fridley, MN, USA) for single-level anterior lumbar
interbody fusion (ALIF) spine surgery. The initial success
of rhBMP-2 with interbody fusion soon led to off-label
use, beyond the initial FDA indication [4]. Unfortunately,
many adverse events have been reported stemming from
its use, including retrograde ejaculation, dysphagia, ectopic
bone formation and potentially cancer, leading clinicians
to question the clinical benefit versus patient safety [4-7].
In 2013, the Yale University Open Data Access (YODA)
Project determined that there was no increased incidence
of retrograde ejaculation, though the potential increase in
cancer was higher in Infuse patients. The YODA study in-
dicated that the increased cancer incidence with rhBMP-2
was 1.9%-3% [8].
The discovery of a new allogeneic tissue processing tech-
nique has provided a way to access BMPs and other growth
factors that are naturally found within bone marrow cells.
OsteoAMP (Advanced Biologics Carlsbad, CA, USA) is an
allogeneic morphogenetic protein that undergoes a novel
tissue processing technique, utilizing angiogenic, mitogenic
and osteoinductive growth factors such as BMP-2, BMP-7,
TGF-β1, aFGF, VEGF, and ANG1, within bone marrow
cells [9-11] and naturally binds them back to the bone graft
being processed. This array of growth factors, beneficial to
bone growth, could offer an alternative to rhBMP-2 and
other current bone graft substitutes on the market today.
The objective of this study was to compare OsteoAMP
allogeneic morphogenetic protein to rhBMP-2 by examin-
ing the radiographic evidence of spinal fusion at various
time points in patients who have undergone lumbar inter-
body fusion and to also examine the costs associated with
the use of these products.
Methods
A dual-arm radiographic analysis was conducted at
three clinical sites to evaluate the fusion success rate of a
commercially available allogeneic morphogenetic protein(OsteoAMP) and rhBMP-2 (Infuse) in lumbar spine sur-
gery. Radiologic review and evaluation were conducted by
a blinded independent radiologist for interbody fusion.
The indications for surgery were symptomatic patients di-
agnosed with degenerative disc disease (DDD), stenosis,
and/or spondylolisthesis (Table 1). Surgical supply costs
for the osteobiologics used were also analyzed to present
an overall value analysis between the two arms.
Patient demographics
Three hundred twenty-one consecutive patients over the
course of 5 years underwent transforaminal lumbar inter-
body fusion (TLIF) or lateral lumbar interbody fusion
(LLIF) between T4 and S1 (522 operative levels/501 inter-
body fusion levels). A group of 95 patients with a mean age
of 54.3 were treated with rhBMP-2 with an average of 1.63
levels per surgery. A group of 226 patients with a mean age
Table 3 Radiologic breakdown for fusion
Radiologic breakdown OsteoAMP (n = 226) rhBMP-2 (n = 95)
Static x-ray 161 38
Computer tomography 65 57
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1.62 levels per surgery (Table 2). On average, patients in the
OsteoAMP arm were 10.5% older than the patients in the
rhBMP-2 cohort.
Materials
Both arms utilized morselized local bone from the surgical
site in combination with the osteobiologic. In the first
arm, OsteoAMP was used in conjunction with the centers'
preferred spinal spacer and fixation system. OsteoAMP
was prepared for use per the instructions by the manufac-
turer (Advanced Biologics). In 58.4% of the OsteoAMP
with local bone cases, bone marrow aspirate (BMA) was
also added. In the second arm, rhBMP-2 was obtained and
loaded onto the absorbable collagen sponge (ACS) as di-
rected by the instructions for use. The rhBMP-2 was then
combined with local autologous bone and packed into an
interbody device. On average, approximately 3.07 mg of
rhBMP-2 was used inside the interbody device per level.Analysis
Patients underwent radiographs (x-ray and/or CT) at
standard postoperative follow-up time points, which were
generally at 6, 13, 26, 52, and 72 weeks postsurgical pro-
cedure. In both arms, the majority of fusion assessments
at each time point were made using static radiographs
(Table 3). Although CT is widely accepted as the standard
for noninvasive assessment of spinal fusion, the increased
radiation exposure and limited equipment availability make
it impractical to subject patients to CT at each visit [12].Figure 1 Radiologic examples of fusion.When evaluated appropriately, literature has shown x-rays
to have similar accuracy when assessing fusion [13].
An independent radiologist made fusion assessments
based on these studies and was blinded to intervention,
product, and surgeon information. Fusion was defined as
any radiographic evidence of bridging across endplates, or
bridging from endplates to interspace disc plugs (Figure 1).
Any radiodensity that obliterates or blurs the lucency be-
tween endplates and plugs that was seen on the postopera-
tive films was considered an evidence of fusion. Fusion
success rate of each patient was then analyzed for both
study arms at each time point. The time frame between
surgical intervention and positive fusion assessment was
calculated and radiologically evident complications of oste-
olysis or ectopic bone formation were reported. Osteobiolo-
gic surgical supply costs were determined by reporting cost
of the implant utilized inside the spinal spacer or interbody
device. If BMA was utilized, the cost of the jamshidi needle
was included in the overall cost. In addition, a secondary
analysis was conducted within the first arm to identify any
correlation between the use of BMA and fusion success.
Results
Fusion success rate
The series of radiographs from each patient were evalu-
ated comparing postoperative x-rays and each consecutive
time point for evidence of fusion to ensure that the opacity
of the biologic or local bone was not a factor in the fusion
assessment. The comparison of both arms demonstrated a
statistically significant difference in the increase of fusion
over each consecutive follow-up time point. Of the 226
patients receiving OsteoAMP, the radiographic fusion ana-
lysis indicated that there was fusion in 59.7% at 6 months,
93.3% at 12 months, and 98.9% at 18 months. Of the 95 pa-
tients receiving rhBMP-2, the analysis indicated that there
was fusion in 39.3% at 6 months, 83.5% at 12 months, and
90.1% at 18 months (Table 4). The results indicated a
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at all time points (p ≤ 0.01) (Figure 2). Total time for fusion
for OsteoAMP was approximately 40% shorter than that of
rhBMP-2 (207.9 and 333.9 days, respectively).
BMA analysis
Of the 132 patients receiving OsteoAMP with BMA, the
radiographic fusion analysis determined that 61.9% of
patients were fused at 6 months, 93.9% at 12 months,
and 99.1% at 18 months. Of the 94 patients receiving
OsteoAMP without BMA, the analysis indicated that
56.7% fused at 6 months, 92.6% at 12 months and 98.7%
at 18 months (Table 5). The difference between groups
was not statistically significant (p = 0.44 at 6 months, p >
0.72 at 12 and 18 months) (Figure 3).
Osteobiologic surgical supply cost analysis
The 95 patient rhBMP-2 arm utilized an average of
2.05 cc (3.07 mg rhBMP-2) inside the interbody device
per level. The supply costs associated with rhBMP-2 was
US$2,523.52 per level. The OsteoAMP arm utilized an
average of 2.5 cc per level inside the spinal spacer. TheFigure 2 TLIF/LLIF fusion rates.supply costs associated with OsteoAMP was US$649.20
per level. The addition of a jamshidi needle used for BMA
collection brought the OsteoAMP weighted cost per level
to US$663.61. The OsteoAMP arm was 80.5% less expen-
sive per patient (73.7% per level) than the rhBMP-2 arm.
Complications
The observation of complications was noted by review-
ing x-rays, CT reports, general radiological assessment,
and surgeon's notes. The rhBMP-2 arm seemed to have
greater radiologically evident adverse events compared
to the OsteoAMP arm. Radiologic evidence of ectopic
bone formation was found in 24.2% of the rhBMP-2
cases compared to 5.3% in patients receiving OsteoAMP
(p < 0.01). There was also greater radiologic evidence of
osteolysis, subsidence, or endplate irregularity in the pa-
tients receiving rhBMP-2 (10.5%) versus OsteoAMP
(5.3%) (p = 0.06) (Figure 4). It should be noted that the
complication observations in both study arms could be
underreported due to the use of other methods besides
CT (standard method) to assess complications.
Discussion
Long-term success following lumbar fusion procedures
is predicated on the integrity of the fused interbody seg-
ments, yet the literature reports that nonunions occur in
10% to 20% of patients with single-level fusions [14-17].
Autograft from the iliac crest has been used successfully;
however, morbidity, limited supply, and additional oper-
ating time associated with autograft harvest have led sur-
geons to consider alternatives.




(%) (n = 132)
OsteoAMP® without BMA





Figure 4 Complication rates.
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plant designs, and less invasive surgical techniques has
greatly improved clinical outcomes [18-20]. There are
many bone graft alternatives today, each with advan-
tages and disadvantages. These bone graft alternatives
will become more highly refined, as our knowledge con-
tinues to improve regarding the biology and mechanics
of spinal fusion [14,21].
The introduction of rhBMP-2 in 2002 provided access
to large quantities of BMP that is only available in trace
amounts in demineralized bone or autograft [22]. Success-
ful fusion results of rhBMP-2 when used in anterior lum-
bar interbody fusions are well documented [23,24]. As
surgeons began to incorporate more minimally invasive
techniques, the off-label use of rhBMP-2 has increased. In
addition, the use in cervical procedures has led to serious
complications [25]. Since then, there have been many at-
tempts to facilitate bone healing and new bone growth to
the same degree as with rhBMP-2. More recently, the use
of stem cells, harvested from cadavers and frozen prior to
surgery, has attempted to deliver viable cells directly to
the surgical site [26]. While there are some reports ofFigure 3 OsteoAMP with and without BMA.successful outcomes in the literature [27], the question
still remains regarding the efficacy of such products [28].
In 2009, OsteoAMP was made commercially available.
Utilizing a novel tissue processing technique, the naturally
occurring growth factors and BMPs from bone marrow
cells are harvested and naturally bound to the cadaver
bone providing a product with angiogenic, mitogenic, and
osteoinductive properties.
In a retrospective study from three centers over a 5-year
period, radiographic fusion (x-ray and CT) was compared
between OsteoAMP and rhBMP-2. The rate of fusion
assessed by an independent radiologist was higher in the
OsteoAMP group at all intervals (p ≤ 0.01). Although ad-
verse events were only determined by radiological review
in this study, OsteoAMP had dramatically fewer complica-
tions than rhBMP-2. These results seem to support the
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found in OsteoAMP. Bone remodeling involves factors,
such as insulin-like growth factors (IGFs), BMPs, and vas-
cular endothelial growth factor (VEGF) to not only stimu-
late cell recruitment and proliferation but also encourage
vascularization [29,30]. OsteoAMP is processed so that
these growth factors are made bioavailable.
Since standard practice at all three centers included the
use of BMA, data was analyzed to identify the efficacy of
BMA. When comparing the fusion results within the
OsteoAMP patient population with and without BMA,
data suggests little difference in fusion success with or
without BMA.
Preparation of OsteoAMP is similar to other bone sub-
stitutes. The product is often reconstituted with blood or
BMA to help with the handling characteristics prior to
use. Unlike rhBMP-2, there is no time required for growth
factor binding. However, aspiration of bone marrow will
be dependent on surgical technique and could be difficult
to mix with the graft if allowed to congeal in the aspiration
syringe.
The inherent risks with the use of allograft tissue and bo-
vine collagen have been discussed in literature for many
years. Allogeneic materials are widely used in orthopedics;
according to the Centers for Disease Control and Preven-
tion, there have been no reports of disease transmission
during the 30-year history of using freeze-dried bone allo-
grafts. However, there have been reports of disease trans-
mission in nonsterile fresh-frozen bone allografts [31], and
literature reports that 3% to 5% of the population is hyper-
sensitive to bovine collagen [32,33]. The established exclu-
sionary criteria combined with recommended processing
procedures established by the American Academy of Tissue
Banking have ensured that freeze-dried bone allografts are
safe for human implantation [34,35].
There were a number of potential limitations in this
study. Each center used different instrumentation and
fixation devices, which may influence some of the re-
sults. The study did not evaluate the clinical outcomes,
and follow-up CTs as well as x-rays were used to assess
fusion over each time point. In addition, the three sur-
geons have unique surgical techniques that may have
contributed to some variability within the results.Conclusions
The results of this study indicated a higher percentage of
patients fused in the OsteoAMP group at all time points
(p ≤ 0.01) (Figure 2). Furthermore, the OsteoAMP arm
was shown to be 80.5% less expensive per patient (73.7%
per level) than the rhBMP-2 arm. The economic analysis
and superior fusion rate results in this study support
OsteoAMP as a cost-effective and viable alternative to
rhBMP-2. Multicenter randomized controlled studies willbe necessary to confirm the efficacy and cost-effectiveness
of OsteoAMP as a superior osteobiologic.
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